

1 **EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN ALONE ON CORONARY**  
2 **ARTERY LESION REDUCTION IN KAWASAKI DISEASE**

3  
4 Ho-Chang Kuo MD PhD<sup>1 2 3#\*</sup>; Ming-Chih Lin MD PhD<sup>4-8#</sup>; Chung-Chih Kao, MD<sup>9#</sup>; Ken-  
5 Pen Weng MD<sup>10#</sup>; Yun Ding PhD<sup>11#</sup>; Chih-Jung Chen MD PhD<sup>1,12,13</sup>; Sheng-Ling Jan MD  
6 PhD<sup>14-16</sup>; Kuang-Jen Chien MD<sup>10</sup>; Chun-Hsiang Ko MS<sup>9</sup>; Chien-Yu Lin MD<sup>17</sup>; Wei-Te Lei  
7 MD<sup>17</sup>; Ling-Sai Chang MD<sup>1,2</sup>; Mindy Ming-Huey Guo MD<sup>1, 2</sup>; Kuender D. Yang MD  
8 PhD<sup>18</sup>; Karl G. Sylvester PhD<sup>11</sup>; Zhi Han PhD<sup>11</sup>; John C. Whitin PhD<sup>11</sup>; Lu Tian PhD<sup>11</sup>;  
9 Henry Chubb MD<sup>11</sup>; Scott R. Ceresnak MD<sup>11</sup>; Doff McElhinney MD<sup>11</sup>; Harvey J. Cohen  
10 MD<sup>11</sup>; Xuefeng B. Ling PhD<sup>11\*</sup>

- 11 1. College of Medicine Chang Gung University Taoyuan Taiwan 33302
- 12 2. Kawasaki Disease Center and Department of Pediatrics Kaohsiung Chang Gung  
13 Memorial Hospital and Chang Gung University College of Medicine Kaohsiung Taiwan  
14 83301
- 15 3. Department of Respiratory Therapy Kaohsiung Chang Gung Memorial Hospital  
16 Kaohsiung Taiwan 83301
- 17 4. Department of Post-Baccalaureate Medicine College of Medicine National Chung  
18 Hsing University Taiwan.
- 19 5. Children's Medical Center Taichung Veterans General Hospital Taichung Taiwan.
- 20 6. School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan.
- 21 7. Department of Food and Nutrition Providence University Taichung Taiwan.
- 22 8. School of Medicine Chung Shan Medical University Taichung Taiwan.
- 23 9. Department of Pediatric Cardiology Tungs' Taichung Metro Harbor Hospital Taiwan.
- 24 10. Congenital Structural Heart Disease Center Department of Pediatrics Kaohsiung  
25 Veterans General Hospital Kaohsiung Taiwan 813414
- 26 11. School of Medicine Stanford University Stanford 94301 USA
- 27 12. Division of Pediatric Infectious Diseases Departments of Pediatrics Chang Gung  
28 Memorial Hospital Taoyuan Taiwan 333
- 29 13. Molecular Infectious Diseases Research Center Chang Gung Memorial Hospital 333  
30 Taoyuan Taiwan
- 31 14. Department of Pediatrics Children's Medical Center Taichung Veterans General  
32 Hospital Taichung Taiwan
- 33 15. Department of Pediatrics School of Medicine National Yang Ming Chiao Tung  
34 University Taipei Taiwan.
- 35 16. Department of Pediatrics School of Medicine Kaohsiung Medical University  
36 Kaohsiung Taiwan.

37 17. Section of Immunology Rheumatology and Allergy Department of Pediatrics Hsinchu  
38 Mackay Memorial Hospital Hsinchu Taiwan.

39 18. MacKay Children's Hospital Taipei Taiwan.

40

41 # Ho-Chang Kuo, Ming-Chih Lin, Chung-Chih Kao, Ken-Pen Weng, Yun Ding have  
42 equal contribution in this work as co-first authors.

43

44 (email address: Ming-Chih Lin [mingclin@gmail.com](mailto:mingclin@gmail.com); Chung-Chih Kao  
45 [cckao2cv@yahoo.com](mailto:cckao2cv@yahoo.com); Ken-Pen Weng [kenpenweng@yahoo.com.tw](mailto:kenpenweng@yahoo.com.tw); Yun Ding  
46 [dingy1979@gmail.com](mailto:dingy1979@gmail.com); Chih-Jung Chen [james.ped@gmail.com](mailto:james.ped@gmail.com); Sheng-Ling Jan  
47 [sljan@vghtc.gov.tw](mailto:sljan@vghtc.gov.tw); Kuang-Jen Chien [kjchien@vghks.gov.tw](mailto:kjchien@vghks.gov.tw); Chun-Hsiang Ko  
48 [adamker01@gmail.com](mailto:adamker01@gmail.com); Chien-Yu Lin [mmhped.lin@gmail.com](mailto:mmhped.lin@gmail.com); Wei-Te Lei  
49 [weite.lei@gmail.com](mailto:weite.lei@gmail.com) ; Ling-Sai Chang [joycejohnsyoko@gmail.com](mailto:joycejohnsyoko@gmail.com); Mindy Ming-Huey  
50 Guo [mindymhguo@cgmh.org.tw](mailto:mindymhguo@cgmh.org.tw); Kuender D. Yang [yangkd.yeh@gmail.com](mailto:yangkd.yeh@gmail.com); Ho-Chang  
51 Kuo [erickuo48@yahoo.com.tw](mailto:erickuo48@yahoo.com.tw); Karl G. Sylvester [karls@stanford.edu](mailto:karls@stanford.edu); Zhi Han  
52 [zhihan01@stanford.edu](mailto:zhihan01@stanford.edu); Lu Tian [lutian@stanford.edu](mailto:lutian@stanford.edu); Henry Chubb  
53 [mhchubb@stanford.edu](mailto:mhchubb@stanford.edu); Scott R. Ceresnak [ceresnak@stanford.edu](mailto:ceresnak@stanford.edu); Doff McElhinney  
54 [doff@stanford.edu](mailto:doff@stanford.edu); John C. Whtin [cuke@stanford.edu](mailto:cuke@stanford.edu); Harvey J. Cohen  
55 [punko@stanford.edu](mailto:punko@stanford.edu); Xuefeng B. Ling [bxling@stanford.edu](mailto:bxling@stanford.edu))

56

57 Corresponding Authors:

58 Ho-Chang Kuo MD PhD, Kawasaki Disease Center and Department of Pediatrics  
59 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of  
60 Medicine Kaohsiung Taiwan ([erickuo48@yahoo.com.tw](mailto:erickuo48@yahoo.com.tw))

61 Xuefeng B. Ling PhD, School of Medicine Stanford University Stanford, USA  
62 ([bxling@stanford.edu](mailto:bxling@stanford.edu))

63

64

65

66

67

68

69

70

71

## 72 **What is New?**

- 73 • This study represents the first multi-center randomized controlled trial  
74 investigating the efficacy of high-dose aspirin or intravenous immunoglobulin  
75 (IVIG) during the acute stage of KD. This study assessed the impact of  
76 discontinuing high-dose aspirin (80–100 mg/kg/day) on the occurrence of CAL  
77 during the acute phase treatment of Kawasaki Disease.
- 78 • No significant differences were observed between high-dose aspirin plus IVIG  
79 treatment and IVIG alone treatment in terms of the frequency of abnormal  
80 coronary artery abnormalities. Additionally, our analysis revealed no statistically  
81 significant differences in either the treatment effect (the number of cases  
82 successfully treated) or prevention effect (the prevention of new cases) between  
83 these two treatments.

## 84 **What Are the Clinical Implications?**

- 85 • Comparison analysis indicated the non-inferiority between two groups with or  
86 without high-dose aspirin.
- 87 • Administering the standard 2 g/kg/day IVIG without high-dose aspirin (80–100  
88 mg/kg/day) during the acute phase therapy for KD does not increase the risk of  
89 coronary artery lesions, which are a primary cause of morbidity and mortality in  
90 KD patients.
- 91 • Addition of high-dose aspirin during initial IVIG treatment is not statistically  
92 significant or clinically meaningful.

93

94

95 **ABSTRACT**

96 **Background:** Though Aspirin and intravenous immunoglobulin (IVIG) remain the  
97 standard treatments for Kawasaki Disease (KD) to minimize coronary artery damage,  
98 the duration and dosage of aspirin are inconsistent across hospitals. However, the lack  
99 of multi-center randomized trials prevents definitive answers to the impact of high-dose  
100 aspirin.

101 **Methods** This clinical trial was structured as a prospective, evaluator-blinded, multi-  
102 center randomized controlled trial with two parallel arms, aiming to assess the  
103 effectiveness of IVIG as a standalone primary therapy of KD in comparison to the  
104 combination of IVIG with high-dose aspirin therapy. KD patients were enrolled between  
105 September, 2016 and August, 2019. A final cohort of 134 patients were randomly  
106 assigned to the standard and test groups with 69 and 65 patients, respectively. The  
107 Standard group received IVIG (2 g/kg) along with aspirin (80-100 mg/kg/day) until fever  
108 subsided for 48 hours. The test group received IVIG (2 g/kg) alone. Following the initial  
109 treatment, both groups received a daily aspirin dose (3-5 mg/kg) for six weeks. The  
110 primary outcome measure was the occurrence of coronary artery lesions (CAL) at the 6-  
111 8 weeks mark. The secondary outcome is IVIG resistance.

112 **Results** The overall rate of CAL in test group decreased from 10.8% at diagnosis to  
113 1.5% and 3.1% at 6 weeks and 6 months, respectively. The CAL rate of standard group  
114 declined from 13.0% to 2.9% and 1.4%, with no statistically significant difference  
115 ( $P>0.1$ ) in the frequency of CAL between the two groups. Furthermore, no statistically  
116 significant differences were found for treatment ( $P>0.1$ ) and prevention ( $P>0.1$ ) effect  
117 between the two groups.

118 **Conclusions:** This marks the first prospective multi-center randomized controlled trial  
119 comparing the standard treatment of KD using IVIG plus high-dose aspirin against IVIG  
120 alone. Our analysis indicates that addition of high-dose aspirin during initial IVIG  
121 treatment is neither statistically significant nor clinically meaningful for CAL reduction.

122 **Registration URL:** <http://www.clinicaltrials.gov>; identifier: NCT02951234

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

## 146 **Introduction**

147 Kawasaki disease (KD) is an acute vasculitis characterized by self-limiting tendencies,  
148 predominantly impacting medium-sized vessels and resulting in coronary artery lesions<sup>1</sup>,  
149 <sup>2</sup> such as dilatations, fistulas, infarctions<sup>3</sup> and aneurysms<sup>4</sup>. Initial treatment typically  
150 includes intravenous immunoglobulin (IVIG) and high-dose aspirin (80–100 mg/kg/day),  
151 which synergistically exert anti-inflammatory effects according to the American Heart  
152 Association (AHA) criteria. It's noteworthy that high-dose aspirin, with its anti-  
153 inflammatory properties, primarily addresses inflammation, while lower doses are  
154 primarily directed at thrombosis.

155 The commonly accepted understanding of CAL, also known as coronary artery  
156 abnormalities (CAA), is based on diagnostic criteria set by the Japanese Ministry of  
157 Health. These criteria involve a maximum internal diameter exceeding 3 mm in children  
158 under 5 years old or exceeding 4 mm in children aged 5 years and above. Furthermore,  
159 the criteria encompass the presence of luminal irregularity, a segmental lumen 1.5 times  
160 larger than an adjacent one, or a visibly irregular luminal contour with a Z score  
161 exceeding 2.5 standard deviations<sup>5-11</sup>. In our previous investigations, which involved a  
162 sequential assessment of coronary artery lesions in 341 Taiwanese children with  
163 Kawasaki disease<sup>12</sup>, we found that 35% of KD patients experienced dilatation during the  
164 acute phase, 17.2% one month after the disease onset, and 10.2% during the two-  
165 month follow-up. Additionally, 4% showed persistent coronary artery lesions lasting for  
166 over one year.

167 Studies suggest that administering intravenous IVIG at a dose of 2 g/kg/day is highly  
168 successful in minimizing the likelihood of CAA in individuals with Kawasaki disease<sup>13-16</sup>.

169 The approved therapy for the acute phase of Kawasaki disease, as recommended by  
170 the American Heart Association (AHA) and the American Academy of Pediatrics (AAP),  
171 includes the administration of IVIG with a single 2 g/kg dose given over 10-12 hours,  
172 along with oral high-dose aspirin at 80-100 mg/kg/day<sup>17</sup>. Although aspirin demonstrates  
173 notable anti-inflammatory effects in high doses and anti-platelet effects in low doses,  
174 there is no prospective study validating its role in diminishing the formation of CAL.  
175 According to two meta-analyses, high-dose aspirin alone does not effectively reduce the  
176 risk of CAA in KD; the reduction is predominantly reliant on the dose of IVIG<sup>18, 19</sup>.  
177 Several studies propose a strong correlation between the incidence of CAL and the  
178 dose of IVIG, indicating that the dosage of aspirin may not have a significant influence.  
179 This suggests that anti-platelet aspirin doses alone might be sufficient during the acute  
180 phase of KD. In a study by Hsieh et al., it was discovered that administering high-dose  
181 aspirin during the acute stage of KD did not affect the response rate to IVIG therapy, the  
182 duration of fever, or the occurrence of CAL when children were treated with a high IVIG  
183 dose (2 g/kg) in a single infusion<sup>13</sup>. In our retrospective analysis, which included 851 KD  
184 patients from two medical centers in Taiwan, we found no noteworthy distinctions  
185 between groups (with or without high-dose aspirin) with regard to gender, IVIG  
186 resistance, CAL formation, and the duration of hospitalization<sup>16</sup>. These retrospective  
187 findings imply that aspirin may offer minimal to no extra advantages when combined  
188 with IVIG therapy during the acute phase of KD.

189 At present, there is a shortage of well-conducted randomized controlled trials (RCTs)  
190 that can determine whether high-dose aspirin should continue to be a fundamental  
191 element of the treatment protocol for children diagnosed with KD. Furusho et al.

192 conducted a study comparing the efficacy of IVIG and aspirin treatment against aspirin  
193 used alone in conjunction with IVIG<sup>20</sup>. According to Sanati et al., the use of high-dose  
194 aspirin does not have a substantial impact on preventing CAA in KD. In a prospective  
195 open-label trial conducted at a single site, administering the standard 2 g/kg/day IVIG  
196 without high-dose aspirin during acute-stage therapy did not elevate the risk of CAL in  
197 62 patients with both typical and atypical KD<sup>21</sup>. Terai et al. discovered that the frequency  
198 of coronary abnormalities in KD was not affected by the aspirin dosage<sup>19</sup>. Furthermore,  
199 Chiang et al. performed a meta-analysis encompassing nine cohorts and a total of  
200 12,182 children. The findings indicate that prescribing low-dose or omitting aspirin  
201 during the acute stage of KD might be linked to a lower occurrence of CAL<sup>22</sup>.

202 The risk associated with aspirin therapy in children with KD is generally considered low  
203 and appears to be comparable to risks reported in other situations. However,  
204 documented cases exist of severe side effects associated with aspirin in children  
205 undergoing KD treatment<sup>16, 23-25</sup>. Given the potential risks of drug toxicity and the limited  
206 robust evidence supporting the prevention of CAL formation, there is a necessity to  
207 reevaluate the role of high-dose aspirin during the acute stage of KD. To address this  
208 concern, we conducted a multi-center, prospective, parallel-group, open-label, non-  
209 inferiority randomized controlled trial to investigate whether high-dose aspirin,  
210 administered during the acute stage of KD, has beneficial effects in preventing the  
211 formation of CAL.

212 A recent investigative study, exploring the heterogeneity of Kawasaki disease, identified  
213 four unique patient clusters. These clusters were delineated according to subjective  
214 clinical features and laboratory results, resulting in the formation of the liver subgroup,



215 band subgroup, node subgroup, and young subgroup<sup>26</sup>. It is noteworthy that these  
216 subgroups exhibited differences in their response to treatment and the outcomes of the  
217 disease, including the risk of coronary artery aneurysm and the rate of intravenous  
218 immunoglobulin resistance. Therefore, in this trial, an approach considering of these  
219 subgroups, following the recent proposal by the UCSD Burns group  
220 (liver/band/node/young), was also implemented. The goal was to compare the treatment  
221 effectiveness for each subgroup of Kawasaki disease between the standard and test  
222 arms, respectively.

223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241

242 **Methods**

243 **Overall Study design:** This study has been structured as a multi-center, prospective,  
244 randomized controlled, evaluator-blinded, non-inferiority trial with two parallel groups.  
245 The aim is to evaluate the effectiveness of intravenous immunoglobulin (IVIG) alone in  
246 comparison to IVIG combined with high-dose aspirin (80-100 mg/kg/day) as the primary  
247 treatment for Kawasaki disease (KD) during the acute stage. The clinical trial was  
248 conducted at five medical centers in Taiwan. Individuals under the age of 18 meeting  
249 the criteria for KD set by the American Heart Association (AHA) were eligible for  
250 enrollment in this study. Individuals with a fever of more than 10 days, previous  
251 treatment of steroids, biologics or were excluded. All patients were administered a high  
252 dose of intravenous immunoglobulin (IVIG) at 2 g/kg over a 12-hour duration, either with  
253 high-dose aspirin (80-100mg/kg/day) in group 1 (standard group) or without aspirin in  
254 group 2 (test group). Following the resolution of fever, low-dose aspirin (3-5 mg/kg/day)  
255 was prescribed for all KD patients for a period of 6-8 weeks or until normal  
256 echocardiography and inflammation laboratory data, in accordance with the guidelines  
257 provided by the AHA. The primary endpoint was identified as the formation of CAL at 6-  
258 8 weeks after enrollment.

259 This study was approved by the Institutional Review Board (IRB) at each site of the  
260 participating institutions, including Linkou Chang Gung Memorial Hospital, Kaohsiung  
261 Chang Gung Memorial Hospital, Taichung Veterans General Hospital, Kaohsiung  
262 Veterans General Hospital, and Tungs' Taichung Metro Harbor Hospital. Informed  
263 consent form (ICF) were signed by the patient or a legal guardian.

264 **NCT registration:** The study was registered at ClinicalTrials.gov with Identifier:

265 [NCT02951234](#) and Release Date: November 3 2016.

266 **Statistics method:** All baseline characteristics were utilized to assess the  
267 comparability of both arms of the trial. The primary outcome evaluation and safety  
268 assessment were conducted using the intention-to-treat (ITT) population. Continuous  
269 variables, including age, gender, hospitalization duration (days), fever duration (days),  
270 height, weight, and clinical manifestations, were presented using either the mean  $\pm$   
271 standard deviation or frequency tables. Data analysis involved the use of the Chi-square  
272 test, independent t -test, Generalized Estimating Equation Model, and repeated  
273 measure analysis of variance (ANOVA) and non-inferiority comparison. The  
274 predetermined two-sided significance level for all statistical tests and confidence  
275 intervals was set at 5%.

276

277

278

279

280

281

282

283

284

## 285 **Results**

### 286 **Patient enrollment and experimental design for the clinical trial**

287 In this investigation, 152 patients diagnosed with Kawasaki Disease (KD) were enrolled  
288 (refer to Figure 1 for the enrollment flowchart). Participants were recruited from five  
289 medical centers in Taiwan. After excluding 18 cases, which included atypical KD cases  
290 or cases without completion of the study protocol, a final cohort of 134 KD patients was  
291 selected for further analysis. The schematic trial design is presented in supplementary  
292 Figure 1. The overall comparison between the test and standard groups is illustrated in  
293 supplementary Figure 1A: 69 patients were allocated to the standard group, receiving  
294 the standard treatment of intravenous immunoglobulin (2 g/kg) along with aspirin (80-  
295 100 mg/kg/day) until their fever subsided for 48 hours. The remaining 65 patients were  
296 assigned to the test group, receiving intravenous immunoglobulin (2 g/kg) alone.  
297 Majority of the fever was resolved within 24 hrs between the two groups after IVIG  
298 treatment. Following the initial treatment, both groups received a daily aspirin dose (3-5  
299 mg/kg) for six weeks. The primary endpoint of this trial is the development of coronary  
300 artery lesions (CAL). Patients underwent 2D echocardiography at baseline, weeks 1, 2,  
301 4, and 6-8, and again at 6 months. At 6 weeks and 6 months, the internal diameter and  
302 Z-score of the left and right main coronary arteries were calculated. CAL was defined for  
303 each age group: over 3.0 mm diameter for children under 5 years, over 4.0 mm for  
304 those 5 years or older, or any irregular luminal contour or Z-score exceeding 2.5.  
305 Throughout the study period, we also compared the treatment effect and prevention  
306 effect, as shown in supplementary Figure 1B and 1C, respectively. For the treatment  
307 effect, we followed CAL patients (Z score >2.5) at the acute phase to the endpoint. For

308 the prevention effect, we followed non-CAL patients (Z score  $\leq 2.5$ ) at the acute phase to  
309 the endpoint.

### 310 **Baseline Characteristics and Group Distribution of Participants in the Study**

311 The percentage of males in the standard group (43%, n=30) and the test group (39%,  
312 n=25) did not exhibit a significant difference (P=0.933). Similarly, no statistically  
313 significant distinctions were observed between the groups in terms of mean weight  
314 (P=0.986) or height (P=0.969). Likewise, the mean ages of the two groups were  
315 comparable (P=0.464). Further analysis revealed no significant differences in baseline  
316 characteristics between the standard and test groups. Specifically, admission days  
317 (P=0.224), white blood cell counts (P=0.053), hemoglobin levels (P=0.138), platelet  
318 counts (P=0.074), GOT levels (P=0.668), and GPT levels (P=0.842) were all similar  
319 between the groups. The standard group exhibited significantly higher C-reactive  
320 protein levels at baseline compared to the test group ( $68.09 \pm 76.66$  vs.  $41.86 \pm 48.06$   
321 mg/L, P=0.021). Baseline coronary artery diameters and Z-scores in both the left main  
322 coronary artery (LMCA), right coronary artery (RCA), and left anterior descending artery  
323 (LAD) did not show significant differences between the groups (P=0.380, P=0.281, and  
324 P=0.788 for diameter; P=0.380, P=0.279, and P=0.674 for Z-score) (Table 1).

### 325 **Clinical Parameters Changes and Dynamics During the Study Period**

326 Throughout the study, there was a noticeable decrease in C-reactive protein (CRP)  
327 levels. Starting from an average baseline of 55.47 mg/L ( $\pm 65.60$  SD), they decreased to  
328 just 1.76 mg/L ( $\pm 8.34$  SD) after 6 weeks. Although statistical analysis initially revealed a  
329 significant difference between the standard and test groups at baseline (P=0.029), this  
330 distinction disappeared by the 6-week mark (P=0.939). Overall, CRP levels exhibited a

331 significant decline across the study duration ( $P < 0.001$ ), and interestingly, the specific  
332 pattern of this decline showed slight differences between the two groups ( $P = 0.031$  for  
333 interaction effect). Both groups demonstrated a general increase in the average platelet  
334 count after IVIG treatment compared to baseline levels. While the average platelet  
335 count changed significantly over time ( $P = 0.001$ ), there were no noticeable differences  
336 between the two groups at either baseline ( $P = 0.359$ ) or 6 weeks after treatment  
337 ( $P = 0.667$ ), and no interaction effect was observed between time and group type  
338 ( $P = 0.123$ ).

339 While white blood cell (WBC) levels exhibited a significant difference between the  
340 standard and test groups at baseline ( $P = 0.035$ ), this distinction disappeared by the 6th  
341 week ( $P = 0.336$ ). Overall, WBC levels displayed a significant decrease across the study  
342 duration ( $P < 0.001$ ), but the rate of decrease did not show a significant difference  
343 between the two groups ( $P = 0.226$ ). Hemoglobin levels increased significantly after 6  
344 weeks in both groups ( $P < 0.001$ ). Although baseline levels differed significantly between  
345 the groups ( $P = 0.020$ ), this difference vanished by the 6th week ( $P = 0.102$ ). The rate of  
346 increase did not exhibit a significant difference between the groups ( $P = 0.874$ ). Two liver  
347 enzymes, glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase  
348 (GPT), were monitored over time. Both enzymes showed a significant decrease  
349 throughout the study ( $P < 0.001$ ). Interestingly, their levels at baseline and after 6 weeks  
350 did not display a significant difference between the two groups ( $P = 0.686$  for GOT and  
351  $P = 0.809$  for GPT), and the rate of decrease over time was also similar ( $P = 0.704$  for  
352 GOT and  $P = 0.842$  for GPT).

### 353 **Coronary Artery Changes and Frequency during study period**

354 The diameter of the left main coronary artery (LMCA) significantly decreased across the  
355 study in both groups ( $p < 0.001$ ), starting at 2.20 mm and reducing to 2.02 mm after 6  
356 months. The rate of reduction was similar between the groups at each time point  
357 ( $P=0.904$  for baseline,  $P=0.479$  for 6th week, and  $P=0.096$  for 6th month), and there  
358 was no significant interaction effect between time and groups ( $P=0.172$ ). Similarly, the  
359 left anterior descending artery (LAD) exhibited a significant narrowing in both groups ( $p$   
360  $< 0.001$ ), starting at 1.75 mm and decreasing to 1.56 mm after 6 months. Once again,  
361 the pattern of reduction was comparable between the groups ( $P=0.188$  for baseline,  
362  $P=0.582$  for 6th week, and  $P=0.138$  for 6th month). However, no interaction effect was  
363 observed between time and groups ( $P=0.675$ ). Likewise, the right coronary artery (RCA)  
364 narrowed significantly over time ( $P = 0.006$ ), from 1.91 mm to 1.81 mm after 6 months,  
365 with no noticeable differences in the rate of reduction between the groups ( $P=0.162$  for  
366 baseline,  $P=0.754$  for 6th week, and  $P=0.290$  for 6th month), and there was no  
367 significant interaction between time and RCA in the groups ( $P=0.827$ ).

368 Overall, at baseline, 10.8% of patients in the test group and 13.0% in the standard  
369 group presented abnormal coronary artery diameter ( $Z$  score  $>2.5$ ) in at least one of the  
370 three coronary arteries. By the 6th month, these percentages reduced to 3.1% and  
371 1.4%, respectively. No significant differences were observed between the groups  
372 regarding the frequency of coronary artery abnormalities during the study period ( $P =$   
373  $0.529$ ). The frequency of coronary artery lesions exhibited a significant decrease  
374 compared to the baseline, starting from the 6th week ( $P=0.002$ ) through the end of the  
375 study period (6th month  $P=0.002$ ). Similarly, no significant differences were observed

376 between the two groups on either LMCA or RCA (detailed analysis in the supplementary  
377 appendix).

378 As for the non-inferiority comparison between the two groups, we consider a difference  
379 in CAL rate of 10% or less as clinically insignificant and the noninferiority margin was  
380 set at 10%. The CAL rate was 12.3% (8/65; 95% confidence interval: 5.5% to 22.8%) in  
381 the test group and 15.9% (11/69; 95% confidence interval: 8.2% to 26.7%) in the  
382 standard care group. The one-sided 97.5% confidence interval for the CAL difference  
383 between the test and standard care group was [-100%, 8.1%]. The upper end of the  
384 confidence interval was below the noninferiority margin of 10%. Therefore, we can  
385 conclude with 97.5% confidence that the CAL rate in the test group was no higher than  
386 that in the standard care group by 10% and the noninferiority was established in current  
387 cohort size of patient numbers in both standard and test groups.

388 In addition to assessing CAL as the primary outcome, we also investigated IVIG  
389 resistance as a secondary outcome. Table S1 indicates that both groups had 3 patients  
390 each with IVIG resistance. There were no significant differences in the rates of IVIG  
391 resistance between the groups ( $P=0.940$ ).

### 392 **Treatment and Prevention Effect on Coronary Artery Changes and Frequency** 393 **during Study Period between Two Groups**

394 Throughout the study duration, we noted that most CAL cases were detected during the  
395 acute phase. However, some patients were initially normal during the acute phase but  
396 later developed CAL at 6 weeks or 6 months, even after receiving IVIG or IVIG plus  
397 high-dose treatment. To compare the treatment effect between the test and standard



398 groups, we conducted statistical analysis of CAL frequency exclusively on the CAL  
399 patients identified during the acute phase.

400 As depicted in Table 4, overall, at the baseline, 10.8% of patients in the test group and  
401 13.0% in the standard group presented abnormal coronary artery diameter (Z  
402 score  $>2.5$ ) in at least one of the three coronary arteries. By the 6th month, all patients  
403 had recovered from CAL. No significant differences were observed between the groups  
404 concerning the frequency of abnormal coronary artery abnormalities during the study  
405 period ( $P = 0.423$ ). The frequency of coronary artery lesions exhibited a significant  
406 decrease compared to the baseline, starting from the 6th week ( $P=0.001$ ) through the  
407 end of the study period (6th month  $P<0.001$ ). Similarly, no significant treatment  
408 differences were observed between the two groups on either LMCA or RCA (detailed  
409 analysis in the supplementary appendix).

410 Following treatment effect, we investigated the preventive impact on the frequency of  
411 Coronary Artery Lesions (CAL) over the study duration for patients who developed CAL  
412 later after IVIG or IVIG plus high-dose aspirin treatment. We performed the same  
413 statistical analysis for the comparison of CAL frequencies, as illustrated in  
414 Supplementary Table 2. No statistical difference was identified between the standard  
415 and test groups. However, a minimal number of newly developed CAL cases were  
416 observed after treatment: 2 in the test group and 1 in the standard group.

## 417 **Discussion**

418 Preventing coronary artery lesions (CALs) is crucial as it represents the most severe  
419 complication of Kawasaki disease (KD). Therefore, determining the ideal aspirin dosage  
420 to prevent this complication is of paramount importance. Aspirin, a salicylate drug,

421 works by inhibiting the production of prostaglandins, which are involved in the  
422 inflammatory response. By exerting anti-inflammatory and antiplatelet effects, aspirin is  
423 thought to play a role in suppressing the inflammatory response and reducing the risk of  
424 blood clots in Kawasaki disease.

425 Our previous study demonstrated that the use of low-dose aspirin in the initial treatment  
426 of children with KD was not linked to fever recurrence or the formation of CAL.

427 Additionally administering high-dose aspirin during the acute stage of KD did not yield  
428 any benefits in terms of inflammation or improved treatment outcomes<sup>16</sup>. This study  
429 represents the first multi-center randomized controlled trial investigating the efficacy of  
430 high-dose aspirin or intravenous immunoglobulin (IVIG) during the acute stage of KD. In  
431 this clinical trial, we assessed the impact of discontinuing high-dose aspirin (80–100  
432 mg/kg/day) on the occurrence of CAL during the acute phase treatment of KD in both  
433 the test and standard groups. The findings revealed that the elimination of high-dose  
434 aspirin did not yield a significant effect on CAL incidence. No significant differences  
435 were observed between the groups in terms of the frequency of abnormal coronary  
436 artery abnormalities during the study period ( $P = 0.529$ ). Through a statistically robust  
437 non-inferiority comparison, we concluded with 97.5% confidence that the CAL rate in  
438 the test group was not higher than that in the standard care group by 10%, establishing  
439 noninferiority with clinical insignificance.

440 Evaluating the overall effectiveness of IVIG treatment entails considering both its  
441 treatment effect (the number of cases successfully treated) and prevention effect (the  
442 prevention of new cases). Our analysis revealed no statistically significant differences in  
443 either the treatment effect ( $P=0.423$ ) or prevention effect ( $P>0.999$ ) between these two

444 groups, despite the occurrence of very limited newly developed CAL cases.

445 Conclusions regarding the prevention effect may require a larger cohort to ensure  
446 robust findings.

447 Furthermore, we performed an analysis to compare the effectiveness in four subgroups  
448 of KD, which were categorized based on subjective clinical features and laboratory  
449 results. Within each of these individual clusters or subgroups, encompassing two  
450 clusters with distinct characteristics, no significant difference was observed in the  
451 reduction of CAL rates at the 6<sup>th</sup> week or 6<sup>th</sup> month after treatment during the acute  
452 phase between the test and standard groups.

453 The primary purpose of administering high-dose aspirin was to elicit anti-inflammatory  
454 effects. As a result, we conducted an analysis comparing efficacy in subgroups  
455 classified based on the acute phase levels of two inflammatory biomarkers: C-reactive  
456 protein (CRP) and platelet count. Consistent with findings in other subgroups, we  
457 identified no significant distinction between the test and standard groups in either the  
458 low (normal range) subgroups for CRP or platelet count, nor in the high (abnormal  
459 range) subgroups. The analysis of these subgroups indicates that the administration of  
460 IVIG treatment alone, without the addition of high-dose aspirin, does not increase the  
461 risk of CAL six weeks or later after the initial treatment. Furthermore, this approach has  
462 wider relevance for KD patients with varied demographic and clinical characteristics.

463 In conclusion, in our trial, high-dose aspirin does not play a significant role in managing  
464 coronary artery lesions in KD patients. Administering the standard 2 g/kg/day IVIG  
465 without high-dose aspirin (80–100 mg/kg/day) during the acute phase therapy for KD

466 does not increase the risk of coronary artery lesions, which are a primary cause of  
467 morbidity and mortality in KD patients. Results from comparison analysis indicate the  
468 non-inferiority between two groups. Therefore, addition of high-dose aspirin during initial  
469 IVIG treatment is not statistically significant or clinically meaningful.

#### 470 **Contributors:**

471 H-CK, HJC and XBL contributed to the study conception and design. M-CL, C-CK, K-PW, YD,  
472 ZH, and LT contributed to the statistical analyses, data entry, and verification. All authors were  
473 involved in the study implementation, data acquisition, and interpretation of the results. All  
474 authors critically reviewed the manuscript, approved the final version for submission, and agree  
475 to be accountable for all aspects of this work.

#### 476 **Declaration of interests**

477 All the authors hereby declare to have no financial interests to disclose regarding this article.

#### 478 **Data sharing**

479 The data that support the findings of this study are available from the corresponding author on  
480 reasonable request. Participant data without names and identifiers will be made available after  
481 approval from the corresponding author and Chang Gung Memorial Hospital. After publication of  
482 study findings, the data will be available for others to request.

#### 483 **Acknowledgements**

484 The authors thank the patients and their carers who participated in this study. This study  
485 received funding from the following grants: CMRPG8J1151 CPRPG8F0791 CPRPG8H0051-2  
486 CMRPG8M1431 CMRPG8M1421 and CMRPG8L1241-2 from Chang Gung Memorial Hospital  
487 and the NSTC 112-2314-B-182-032-MY3 from National Science and Technology Council of  
488 Taiwan to Dr. Ho; and 1R41TR004351-01 from US National Institute of Health to Dr. Ling.

489 Although these institutes provided financial support, they had no influence on the way in which  
490 we collected analyzed or interpreted the data or wrote this manuscript.

#### 491 **Figure legends**

492 **Figure 1: Consort diagram for patient enrollment.** 152 KD patients were enrolled  
493 from five clinical centers. After removing 18 incomplete KD cases a final 134 KD  
494 patients were assigned into test and standard group for trial.

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512 **Reference**

- 513 1. Burns JC, Glode MP. Kawasaki syndrome. *Lancet*. 2004;364(9433):533-44. doi:  
514 10.1016/S0140-6736(04)16814-1. PubMed PMID: 15302199.
- 515 2. Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA.  
516 Management of Kawasaki disease. *Arch Dis Child*. 2014;99(1):74-83. Epub 20131025.  
517 doi: 10.1136/archdischild-2012-302841. PubMed PMID: 24162006; PMCID:  
518 PMC3888612.
- 519 3. Liang CD, Kuo HC, Yang KD, Wang CL, Ko SF. Coronary artery fistula  
520 associated with Kawasaki disease. *Am Heart J*. 2009;157(3):584-8. Epub 20090203.  
521 doi: 10.1016/j.ahj.2008.11.020. PubMed PMID: 19249434.
- 522 4. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC,  
523 Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME,  
524 Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever E, Kawasaki D,  
525 Council on Cardiovascular Disease in the Y, American Heart A, American Academy of P.  
526 Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for  
527 health professionals from the Committee on Rheumatic Fever, Endocarditis and  
528 Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart  
529 Association. *Circulation*. 2004;110(17):2747-71. doi:  
530 10.1161/01.CIR.0000145143.19711.78. PubMed PMID: 15505111.
- 531 5. Akagi T, Rose V, Benson LN, Newman A, Freedom RM. Outcome of coronary  
532 artery aneurysms after Kawasaki disease. *J Pediatr*. 1992;121(5 Pt 1):689-94. doi:  
533 10.1016/s0022-3476(05)81894-3. PubMed PMID: 1432415.

- 534 6. Shulman ST, De Inocencio J, Hirsch R. Kawasaki disease. *Pediatr Clin North*  
535 *Am.* 1995;42(5):1205-22. doi: 10.1016/s0031-3955(16)40059-3. PubMed PMID:  
536 7567192.
- 537 7. Yu HR, Kuo HC, Sheen JM, Wang L, Lin IC, Wang CL, Yang KD. A unique  
538 plasma proteomic profiling with imbalanced fibrinogen cascade in patients with  
539 Kawasaki disease. *Pediatr Allergy Immunol.* 2009;20(7):699-707. Epub 20090112. doi:  
540 10.1111/j.1399-3038.2008.00844.x. PubMed PMID: 19170925.
- 541 8. Wu MT, Hsieh KS, Lin CC, Yang CF, Pan HB. Images in cardiovascular medicine.  
542 Evaluation of coronary artery aneurysms in Kawasaki disease by multislice computed  
543 tomographic coronary angiography. *Circulation.* 2004;110(14):e339. doi:  
544 10.1161/01.CIR.0000143374.80173.EF. PubMed PMID: 15466653.
- 545 9. Weng KP, Ho TY, Chiao YH, Cheng JT, Hsieh KS, Huang SH, Ou SF, Liu KH,  
546 Hsu CJ, Lu PJ, Hsiao M, Ger LP. Cytokine genetic polymorphisms and susceptibility to  
547 Kawasaki disease in Taiwanese children. *Circ J.* 2010;74(12):2726-33. Epub 20101030.  
548 doi: 10.1253/circj.cj-10-0542. PubMed PMID: 21048327.
- 549 10. Weng KP, Hsieh KS, Ho TY, Huang SH, Lai CR, Chiu YT, Huang SC, Lin CC,  
550 Hwang YT, Ger LP. IL-1B polymorphism in association with initial intravenous  
551 immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. *Circ J.*  
552 2010;74(3):544-51. Epub 20100118. doi: 10.1253/circj.cj-09-0664. PubMed PMID:  
553 20081319.
- 554 11. Weng KP, Hsieh KS, Hwang YT, Huang SH, Lai TJ, Yuh YS, Hou YY, Lin CC,  
555 Huang SC, Chang CK, Lin MW, Ger LP. IL-10 polymorphisms are associated with

- 556 coronary artery lesions in acute stage of Kawasaki disease. *Circ J.* 2010;74(5):983-9.  
557 Epub 20100326. doi: 10.1253/circj.cj-09-0801. PubMed PMID: 20339193.
- 558 12. Kuo HC, Yu HR, Juo SH, Yang KD, Wang YS, Liang CD, Chen WC, Chang WP,  
559 Huang CF, Lee CP, Lin LY, Liu YC, Guo YC, Chiu CC, Chang WC. CASP3 gene single-  
560 nucleotide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children. *J*  
561 *Hum Genet.* 2011;56(2):161-5. Epub 20101216. doi: 10.1038/jhg.2010.154. PubMed  
562 PMID: 21160486.
- 563 13. Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute  
564 Kawasaki disease: aspirin's role in the febrile stage revisited. *Pediatrics.*  
565 2004;114(6):e689-93. Epub 20041115. doi: 10.1542/peds.2004-1037. PubMed PMID:  
566 15545617.
- 567 14. Lee G, Lee SE, Hong YM, Sohn S. Is high-dose aspirin necessary in the acute  
568 phase of kawasaki disease? *Korean Circ J.* 2013;43(3):182-6. Epub 20130331. doi:  
569 10.4070/kcj.2013.43.3.182. PubMed PMID: 23613695; PMCID: PMC3629244.
- 570 15. Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous  
571 immunoglobulin in the treatment of Kawasaki syndrome. *Clin Pediatr (Phila).*  
572 2002;41(8):597-601. doi: 10.1177/000992280204100807. PubMed PMID: 12403377.
- 573 16. Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH. High-Dose Aspirin is  
574 Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in  
575 Kawasaki Disease. *PLoS One.* 2015;10(12):e0144603. Epub 20151210. doi:  
576 10.1371/journal.pone.0144603. PubMed PMID: 26658843; PMCID: PMC4686074.
- 577 17. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M,  
578 Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E,



- 579 American Heart Association Rheumatic Fever E, Kawasaki Disease Committee of the  
580 Council on Cardiovascular Disease in the Y, Council on C, Stroke N, Council on  
581 Cardiovascular S, Anesthesia, Council on E, Prevention. Diagnosis, Treatment, and  
582 Long-Term Management of Kawasaki Disease: A Scientific Statement for Health  
583 Professionals From the American Heart Association. *Circulation*. 2017;135(17):e927-  
584 e99. Epub 20170329. doi: 10.1161/CIR.0000000000000484. PubMed PMID: 28356445.
- 585 18. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary  
586 artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and  
587 immunoglobulin treatment. *Pediatrics*. 1995;96(6):1057-61. PubMed PMID: 7491221.
- 588 19. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki  
589 disease is highly dependent on gamma globulin dose but independent of salicylate  
590 dose. *J Pediatr*. 1997;131(6):888-93. doi: 10.1016/s0022-3476(97)70038-6. PubMed  
591 PMID: 9427895.
- 592 20. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T,  
593 Tamura T, Hirose O, Manabe Y, Yokoyama T, et al. Intravenous gamma-globulin for  
594 Kawasaki disease. *Acta Paediatr Jpn*. 1991;33(6):799-804. doi: 10.1111/j.1442-  
595 200x.1991.tb02611.x. PubMed PMID: 1801560.
- 596 21. Sanati F, Bagheri M, Eslami S, Khalooei A. Evaluation of high-dose aspirin  
597 elimination in the treatment of Kawasaki disease in the incidence of coronary artery  
598 aneurysm. *Ann Pediatr Cardiol*. 2021;14(2):146-51. Epub 20210416. doi:  
599 10.4103/apc.APC\_206\_20. PubMed PMID: 34103852; PMCID: PMC8174624.
- 600 22. Chiang MH, Liu HE, Wang JL. Low-dose or no aspirin administration in acute-  
601 phase Kawasaki disease: a meta-analysis and systematic review. *Arch Dis Child*.

602 2021;106(7):662-8. Epub 20201110. doi: 10.1136/archdischild-2019-318245. PubMed  
603 PMID: 33172886.

604 23. Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC. Gastrointestinal  
605 hemorrhage complicating aspirin therapy in acute Kawasaki disease. *J Pediatr*.  
606 1996;128(5 Pt 1):701-3. doi: 10.1016/s0022-3476(96)80140-5. PubMed PMID:  
607 8627447.

608 24. Wei CM, Chen HL, Lee PI, Chen CM, Ma CY, Hwu WL. Reye's syndrome  
609 developing in an infant on treatment of Kawasaki syndrome. *J Paediatr Child Health*.  
610 2005;41(5-6):303-4. doi: 10.1111/j.1440-1754.2005.00617.x. PubMed PMID: 15953335.

611 25. Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of  
612 one case. *Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi*. 1992;33(1):67-71. PubMed  
613 PMID: 1626454.

614 26. Wang H, Shimizu C, Bainto E, Hamilton S, Jackson HR, Estrada-Rivadeneira D,  
615 Kaforou M, Levin M, Pancheri JM, Dummer KB, Tremoulet AH, Burns JC. Subgroups of  
616 children with Kawasaki disease: a data-driven cluster analysis. *Lancet Child Adolesc*  
617 *Health*. 2023;7(10):697-707. Epub 20230817. doi: 10.1016/S2352-4642(23)00166-9.  
618 PubMed PMID: 37598693; PMCID: PMC10756500.

619

620

621

622

623

624

625

626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640

**Table 1 Baseline Characteristics and Group Distribution of Participants in the Study**

Variable	Mean ± SD			P
	Total (n=134)	Standard Group (n=69)	Test Group (n=65)	
Gender, n (%)				
Male	82 (61.2)	43 (62.3)	39 (60.0)	0.783
Female	52 (38.8)	26 (37.7)	26 (40.0)	
Age (years)	1.77±1.31	1.85±1.43	1.69±1.17	0.464
Weight (Kg)	11.14±3.56	11.13±3.56	11.14±3.58	0.986
Height (cm)	81.83±13.13	81.87±13.85	81.79±12.44	0.969
Admission (days)	5.12±1.88	4.93±1.86	5.32±1.89	0.224
White blood cell (WBC, 1000/μL)	14.19±5.63	15.11±6.21	13.23±4.80	0.053
Hemoglobin (g/dL)	11.26±1.01	11.13±0.94	11.39±1.07	0.138
Platelet (1000/μL)	335.20±102.30	350.70±111.20	319.00±90.09	0.074
CRP (mg/L)	55.47±65.60	68.09±76.66	41.86±48.06	0.021*
GOT (U/L)	95.38±143.70	90.20±120.80	101.30±166.80	0.668
GPT (U/L)	102.50±127.70	140.70±139.60	100.30±114.80	0.842
LCMA diameter (mm)	2.20±0.44	2.23±0.48	2.17±0.39	0.380
LCMA Z score	1.19±0.98	1.26±1.00	1.11±0.96	0.380
LAD diameter (mm)	1.75±0.42	1.74±0.44	1.76±0.40	0.788
LAD Z score	0.81±0.74	0.78±0.77	0.84±0.72	0.674
RAC diameter (mm)	1.91±0.43	1.87±0.44	1.95±0.41	0.281
RAC Z score	1.16±0.84	1.08±0.90	1.24±0.78	0.279

\*  $P < 0.05$

SD: Standard deviation, CRP: C-reactive protein, GOT: Glutamic oxaloacetic transaminase, GPT: Glutamic pyruvic transaminase, LMCA: Left main coronary artery, RCA: Right coronary artery, LAD: Left anterior descending

641

642

643

644 **Table 2 Analysis of variance of the effects of treatment in terms of the group,**  
645 **time, and their interaction (\*Difference between two group, \*\*Difference between the**  
646 **three times, \*\*\*Interaction effect between time and group)**

647

648

649 CRP: C-reactive protein, WBC: White blood cell; GOT: Glutamic oxaloacetic

Variable	Time	Mean ± SD			P*	P**	P***
		Standard Group	Test Group	Total			
CRP	Baseline	68.09±76.66	41.86±48.06	55.47±65.60	0.029	<0.001	0.031
	after 6 weeks	1.82±8.78	1.70±7.91	1.76±8.34	0.939		
	after 6 months	N.D.	N.D.	N.D.			
Platelet	Baseline	350.70±111.20	319.00±90.09	335.20±102.30	0.359	0.001	0.123
	after 6 weeks	372.70±114.20	380.80±87.61	376.50±102.10	0.667		
	after 6 months	N.D.	N.D.	N.D.			
WBC	Baseline	15.11±6.21	13.23±4.80	14.19±5.63	0.035	<0.001	0.226
	after 6 weeks	9.15±3.23	8.64±2.54	8.90±2.92	0.336		
	after 6 months	N.D.	N.D.	N.D.			
Hemoglobin	Baseline	11.13±0.94	11.39±1.07	11.26±1.01	0.027	<0.001	0.874
	after 6 weeks	11.86±1.03	12.16±0.98	12.01±1.02	0.102		
	after 6 months	N.D.	N.D.	N.D.			
GOT	Baseline	90.20±120.80	101.30±166.80	95.38±143.70	0.686	<0.001	0.704
	after 6 weeks	38.93±10.37	39.27±7.98	39.09±9.29	0.854		
	after 6 months	N.D.	N.D.	N.D.			
GPT	Baseline	104.70±139.60	100.30±114.80	102.50±127.70	0.869	<0.001	0.842
	after 6 weeks	18.78±9.51	19.19±7.21	18.97±8.46	0.802		
	after 6 months	N.D.	N.D.	N.D.			
LMCA diameter	Baseline	2.23±0.48	2.17±0.39	2.20±0.44	0.904	<0.001	0.172
	after 6 weeks	2.05±0.45	1.99±0.39	2.02±0.42	0.479		
	after 6 months	1.97±0.38	2.07±0.32	2.02±0.35	0.096		
LAD diameter	Baseline	1.74±0.44	1.76±0.40	1.75±0.42	0.188	<0.001	0.675
	after 6 weeks	1.55±0.39	1.59±0.36	1.57±0.38	0.582		
	after 6 months	1.50±0.39	1.61±0.36	1.56±0.38	0.138		
RCA diameter	Baseline	1.87±0.44	1.95±0.41	1.91±0.43	0.162	0.006	0.827
	after 6 weeks	1.75±0.41	1.77±0.39	1.76±0.40	0.754		
	after 6 months	1.78±0.37	1.85±0.34	1.81±0.36	0.290		

650 transaminase, GPT: Glutamic pyruvic transaminase, LMCA: Left main coronary artery,  
651 RCA: Right coronary artery, LAD: Left anterior descending.

652 

CAL	Group	Abnormal (Z score>2.5)	Baseline	At 6 <sup>th</sup> week	At 6 <sup>th</sup> months	P
-----	-------	------------------------	----------	-------------------------	---------------------------	---

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678 **Table 3 Comparison frequency of abnormal coronary arteries diameter in term of**  
679 **groups type and time-combined effect**

680	LMCA	Test	Yes	4 (6.2)	0 (0.0)	1 (1.5)	0.423
681			No	61 (93.8)	65 (100.0)	64 (98.5)	
682		Standard	Yes	6 (8.7)	2 (2.9)	0 (0.0)	
683			No	63 (91.3)	67 (97.1)	69 (100.0)	
684		<i>P-value</i>		Ref	0.018	0.006	
685	LAD	Test	Yes	0 (0.0)	0 (0.0)	0 (0.0)	N.A.
686			No	65 (100.0)	65 (100.0)	65 (100.0)	
687		Standard	Yes	0 (0.0)	0 (0.0)	0 (0.0)	
688			No	69 (100.0)	69 (100.0)	69 (100.0)	
689		<i>P-value</i>		Ref	N.A.	N.A.	
690	RCA	Test	Yes	4 (6.2)	1 (1.5)	1 (1.5)	0.423
691			No	61 (93.8)	64 (98.5)	64 (98.5)	
692		Standard	Yes	3 (4.3)	1 (1.4)	1 (1.4)	
693			No	66 (95.7)	68 (98.5)	68 (98.5)	
694		<i>P-value</i>		Ref	0.090	0.090	
695	Overall	Test	Yes	7 (10.8)	1 (1.5)	2 (3.1)	0.529
696			No	58 (89.2)	64 (98.5)	63 (96.9)	
697		Standard	Yes	9 (13.0)	2 (2.9)	1 (1.4)	
698			No	60 (87.0)	67 (97.1)	68 (98.5)	
699		<i>P-value</i>		Ref	0.002	0.002	

700  
701

LMCA: Left main coronary artery, RCA: Right coronary artery, LAD: Left anterior descending.

702  
703  
704  
705  
706  
707

**Table 4 Comparison frequency of abnormal coronary arteries diameter in term of groups type and time-treatment effect**

708  
709

CAL	Group	Abnormal (Z score>2.5)	Baseline	At 6 <sup>th</sup> week	At 6 <sup>th</sup> months	P	
LMCA	Test	Yes	4 (6.2)	0 (0.0)	0 (0.0)	0.225	
		No	61 (93.8)	65 (100.0)	65 (100.0)		
	Standard	Yes	6 (8.7)	1 (1.4)	0 (0.0)		
		No	63 (91.3)	68 (98.5)	69 (100.0)		
	<i>P-value</i>			Ref	0.006	0.001	
	LAD	Test	Yes	0 (0.0)	0 (0.0)	0 (0.0)	N.A.
No			65 (100.0)	65 (100.0)	65 (100.0)		
Standard		Yes	0 (0.0)	0 (0.0)	0 (0.0)		
		No	69 (100.0)	69 (100.0)	69 (100.0)		
<i>P-value</i>			Ref	N.A.	N.A.		
RCA		Test	Yes	4 (6.2)	1 (1.5)	0 (0.0)	0.184
	No		61 (93.8)	64 (98.5)	65 (100.0)		
	Standard	Yes	3 (4.3)	0 (0.0)	0 (0.0)		
		No	66 (95.7)	69 (100.0)	69 (100.0)		
	<i>P-value</i>			Ref	0.066	0.008	
	Overall	Test	Yes	7 (10.8)	1 (1.5)	0 (0.0)	0.423
No			58 (89.2)	64 (98.5)	65 (100.0)		
Standard		Yes	9 (13.0)	1 (1.4)	0 (0.0)		
		No	60 (87.0)	68 (98.5)	69 (100.0)		
<i>P-value</i>			Ref	0.001	<0.001		

710

711 LMCA: Left main coronary artery, RCA: Right coronary artery, LAD: Left anterior  
 712 descending.

713



**Figure 1 Consort diagram for patient enrollment.**

